Iron carboxymaltose group. Total dose of intravenous ferric carboxymaltose (Iroprem®) needed to correct anemia and replenish iron stores will be calculated using the Ganzoni formula (28) modified to include adjustment for baseline iron status: prepregnancy weight in kilograms X (15-baseline Hb) X 2.4 + 500. Fifteen is the target Hb in g/dL, 2.4 is a unit less conversion constant and 500 is the target iron stores in mg. The maximal dose administered in a single day will not exceed 15 mg/kg (current weight) or 1000 mg (for participants with body weight > 67 kg). If total calculated dose will exceed 15 mg/kg or 1000 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.

Total dose of intravenous iron isomaltoside (Monofer®) needed to correct anemia and replenish iron stores will be calculated as described above. The maximal dose administered in a single day will not exceed 20 mg/kg (current weight) or 1500 mg (for participants with body weight > 75 kg). If total calculated dose will exceed 20 mg/kg or 1500 mg, subsequent doses will be administered weekly until the total calculated dose will be reached.

Iron sulphate group. Participants will receive oral ferrous sulphate (Tardyfer®) 160 mg daily for 6 weeks with instruction to take two tablets by mouth once daily 1 hour before meal. They will receive no additional iron supplementation.

Postpartum Anemia Nos

Iron-deficiency

Pospartum women will be included in the study.

Intravenous iron carboxymaltose application

Iron Carboxymaltose

Iron Isomaltoside

Ferrous sulphate

UMC Ljubljana

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Randomized Trial Comparing Intravenous Iron Carboxymaltose, Intravenous Iron Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Multidimensional Fatigue Inventory (MFI) score at 6 weeks postpartum. The MFI is a 20-item self-report instrument designed to measure fatigue. Items are scored 1-5, with 10 positively phrased items reverse scored (this concerns following items: 2, 5, 9, 10, 13, 14, 16, 17, 18, 19). For each of the 5 scales (general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue) a total score is calculated by summation of the scores of the individual items. Scores can range from the minimum of 4 to the maximum of 20. Higher scores indicate a higher degree of fatigue.

Edinburgh Postnatal Depression Scale (EPDS) score at 6 weeks postpartum. EPDA is a 10-item questionnaire which evaluates different depression symptoms, such as guilt feeling, sleep disturbance, low energy, anhedonia, and suicidal ideation. Overall assessment is done by total score, which is determined by adding together the scores for each of the 10 items. Each answer is given a score of 0 to 3 . The maximum score is 30. Higher scores indicate more depressive symptoms. A score of more than 10 suggests minor or major depression may be present.

Mean hemoglobin level at 6 weeks postpartum

Proportion of participants with hemoglobin level > 120 g/L at 6 weeks postpartum

Proportion of participants with ferritin level > 50 mcg/L

Compliance with oral ferrous sulphate treatment

Side effects of all three study treatments in mothers (e.g. constipation, headache, infusion site burning) and infants (e.g. constipation, erythema, diarrhea, abdominal pain, upper respiratory tract infection)

The investigators will be willing to share IPD after study completion.

Miha Lucovnik

assistant professor

University Medical Centre Ljubljana

Thalidomide 100mg per day after the radical resection HCC

No adjuvant Thalidomide treatment after curative hepatic resection

Hepatocellular Carcinoma

Recurrence

Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period

carboxylase/خستگی پزشکی

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی